Inpatient Versus Outpatient Treatment Related to Exacerbation Episodes In Chronic Obstructive Pulmonary Disease (Copd) From A Public Mexican Institutional Perspective)

Abstract

Spiromax® inhaler was also investigated. Methods: The eligible adult patient population was based on current confirmed UK asthma and COPD diagnosis rates, with the proportion receiving FDCs based on market research data. Costs of FDCs and scheduled and unscheduled healthcare events were taken from publicly available UK sources. Frequency of poor inhalation technique with the market-leading DPIs, and the associated increased risk of unscheduled healthcare events, were taken from a large (n=1,664) cross-sectional, Italian observational study, with the estimated reduction in the proportion of patients with poor inhalation technique with DuoResp® Spiromax® based on a conservative assumption. Results: The model estimated that 400,926 adult patients use Symbicort® Turbohaler® and 357,008 Seretide® Accuhaler® annually and were therefore eligible for treatment with DuoResp® Spiromax®, with 174,403 and 123,168 of these exhibiting poor inhalation technique, respectively. Assuming a hypothetical uptake of DuoResp® Spiromax® reaching 13% in year 4 and 5, and its current UK price, the model predicted drug cost savings totalling £65.57 million over five years. Furthermore, 64,845 unscheduled healthcare events could be avoided due to the predicted improvement in inhalation technique with DuoResp® Spiromax® compared with these DPIs, resulting in further savings of £4.78 million. ConClusions: DuoResp® Spiromax® is likely to offer budgetary savings compared with market-leading DPIs, with further cost savings potentially resulting from improved inhalation technique.